The research team, based at Ludwig-Maximilians-University Munich, took their laboratory into the field, following healthy volunteers on a five-day expedition through the Italian Alps in August 2022. Rather than simulating altitude in a hypoxic chamber, the investigators measured participants under genuine expedition conditions, ascending from the valley town of Varallo at 450 meters to the Capanna Regina Margherita at 4554 meters, one of the highest permanently staffed buildings in Europe. At each stage of the climb, participants completed structured headache questionnaires, rated their pain on a numerical scale from zero to ten, filled in the 2018 Lake Louise Acute Mountain Sickness Score, and provided samples of tear fluid for neuropeptide analysis. Certified mountain guides from the International Federation of Mountain Guides Association accompanied every group, and the protocol was approved by the university ethics committee.

The choice of tear fluid as the sampling medium is one of the study’s most intriguing technical features. Collecting blood at 4554 meters is cumbersome, and obtaining cerebrospinal fluid is out of the question in a field setting. Tear fluid, by contrast, can be aspirated from the lateral corner of each eye with a thin plastic capillary in under a minute, provided the investigator avoids irritating the ocular surface and triggering reflex tearing, which would dilute the sample. The researchers collected fluid from both eyes, pooled it after confirming no significant left-right differences at baseline, stabilized it in protein extraction reagent, kept it on dry ice, and later quantified CGRP concentrations with a commercial enzyme-linked immunosorbent assay read in duplicate on a spectrometer. The approach offers a noninvasive window into a neuropeptide that is otherwise difficult to track outside a hospital laboratory.

CGRP itself is a potent vasodilatory neuropeptide released from the endings of the trigeminovascular system, the network of sensory nerves that innervates the blood vessels of the brain’s protective membranes. Decades of work have established it as a central player in migraine: levels rise during spontaneous attacks, injecting CGRP can provoke migraine-like headaches in susceptible patients, and drugs that block the molecule or its receptor have transformed migraine prevention in recent years. Because high-altitude headache shares clinical features with migraine, including aggravation by physical activity, and because a history of migraine is a known risk factor for altitude headache, the Munich team hypothesized that hypobaric hypoxia might activate the same trigeminovascular pathway and drive CGRP release at altitude.

The expedition data gave that hypothesis substantial support. Of the 24 originally recruited participants, 13 completed the full protocol with usable tear samples, a reduction the authors attribute to early terminations and insufficient fluid volumes. Among these 13, headache burden climbed steadily with altitude. No one reported headache at baseline in the valley, but 46 percent did so after reaching 3498 meters on day two, 62 percent at 3647 meters on day three, and a striking 85 percent at 4554 meters on day four, when the mean pain score reached 3.2 on the ten-point scale. Eight participants, or 62 percent, fulfilled the formal ICHD-3 criteria for high-altitude headache at the highest hut, a figure consistent with the 36 to 73 percent incidence reported in earlier studies at comparable elevations.

The CGRP measurements revealed a pattern that was invisible in the group average. Across all participants, tear fluid CGRP levels at 4554 meters were not significantly different from baseline values, a result that on its own might have suggested the neuropeptide was irrelevant. But when the researchers split the cohort by symptom severity, a clear signal emerged. The six participants who developed moderate-to-severe headaches, with mean pain scores of 5.0, showed a substantial rise in tear fluid CGRP, averaging an increase of 1.86 nanograms per milliliter from baseline, while the seven participants with only mild headaches actually showed a slight decrease of 0.19 nanograms per milliliter. The difference between the groups was statistically significant, and baseline CGRP levels had been virtually identical, indicating that the elevation was triggered by the altitude exposure itself rather than reflecting a pre-existing trait.

The same dissociation appeared when participants were classified by diagnosis. Those meeting ICHD-3 criteria for high-altitude headache showed a mean CGRP increase of 1.49 nanograms per milliliter, compared with a decrease of 0.42 in those without the diagnosis. Even more striking, six participants, nearly half the cohort, developed a headache that met criteria for migraine without aura, complete with moderate-to-severe pulsating pain, nausea or vomiting in half of cases, and photophobia in some. These migraine-like sufferers reported higher pain intensity and a significantly larger CGRP rise of 1.75 nanograms per milliliter than their symptom-free counterparts. Notably, oxygen saturation, which hovered around 78 percent at the highest altitude for everyone, did not differ between headache and non-headache groups, suggesting that the degree of hypoxia alone did not determine who suffered.

The cerebral circulation told a quieter story. Using transcranial color-coded duplex sonography at baseline and at 4554 meters, the team measured blood flow velocity in the middle cerebral arteries on both sides, calculating mean flow velocities and the Lindegaard index to screen for vasospasm. Neither the presence of high-altitude headache nor of migraine-like symptoms was associated with differences in flow velocity or in the change from baseline, and there was no evidence of vasospasm in any group. This absence of a vascular signature is itself informative: it shifts attention away from simple blood-vessel constriction or dilation as the cause of altitude pain and toward neurogenic inflammation, the process by which activated trigeminal nerves release CGRP and other mediators directly around meningeal vessels.

Disentangling the two candidate triggers of that activation, hypoxia and reduced barometric pressure, remains difficult in a field design, and the authors are careful on this point. Animal experiments have shown that lowering atmospheric pressure by as little as 40 hectopascals increases firing in neurons of the spinal trigeminal nucleus, particularly those with corneal afferents, and human volunteers exposed to modest pressure drops in a climate chamber have reported head compression and mild-to-moderate headache. Meanwhile, chamber studies of pure normobaric hypoxia have induced headache in roughly 80 percent of healthy volunteers and elevated plasma CGRP in migraine patients. Because tear fluid CGRP did not rise uniformly across the expedition and did not track oxygen saturation, the new data hint that hypoxia by itself may be insufficient, and that the interplay of low pressure and low oxygen, possibly amplified in susceptible individuals, is what ignites the trigeminovascular system.

The study’s limitations are real and acknowledged by its authors. Thirteen completers is a small sample, nearly half the original cohort was excluded, tear fluid CGRP has not been formally validated against plasma or cerebrospinal fluid concentrations, and an observational design cannot establish whether the neuropeptide rise precedes the pain or merely accompanies it. Even so, the implications are tantalizing. If CGRP release genuinely drives altitude headache, then the CGRP-targeted monoclonal antibodies and small-molecule antagonists that have revolutionized migraine care might, in principle, be repurposed as prophylaxis for mountaineers, an idea the authors say deserves interventional study. And if tear fluid proves to be a reliable surrogate medium, field researchers could gain a practical, needle-free biomarker for headache severity in some of the most remote environments on Earth, from Himalayan base camps to aerospace settings, where the biology of low pressure and low oxygen has long outpaced our ability to measure it.

Subject of Research: The role of the neuropeptide CGRP in high-altitude headache and migraine-like headache during hypobaric hypoxia

Article Title: The Role of Calcitonin Gene‐Related Peptide in High‐Altitude Headache: A Prospective Field Study

Article References: Schniepp, R., Karrasch, L., Breitenstein, H., Straube, A., & Kamm, K. (2026). The Role of Calcitonin Gene‐Related Peptide in High‐Altitude Headache: A Prospective Field Study. Annals of Clinical and Translational Neurology, 13(10), 2046-2056. https://doi.org/10.1002/acn3.70374

Image Credits: AI Generated

DOI: 10.1002/acn3.70374

Keywords: high-altitude headache, CGRP, migraine, hypobaric hypoxia, trigeminovascular system, tear fluid biomarker, acute mountain sickness, transcranial duplex sonography, neuropeptides, Alps expedition, headache disorders, neurology

Acute mountain sickness is far more than an inconvenience. Headache, dizziness, nausea, vomiting, and fatigue can degrade judgment and performance, and in severe cases the condition can progress to high-altitude cerebral edema or high-altitude pulmonary edema, both of which are life threatening. As modern transportation makes it possible to fly from Beijing to the Tibetan plateau in under five hours, the number of people exposed to sudden, severe hypoxia has risen sharply. Yet the tools available to predict who will fall ill remain frustratingly limited, often requiring hypoxic gas generators, hypobaric chambers, blood biomarkers, or expensive imaging equipment that is unrealistic for field deployment.

The research team, drawn from Tsinghua University and collaborating institutions, recruited 48 healthy low-altitude residents aged 18 to 31 years with no high-altitude exposure in the preceding year. After strict screening for cardiovascular disease, chronic respiratory conditions, hypertension, and medications affecting cardiopulmonary function, 44 participants completed the full protocol. At 50 meters above sea level, each volunteer performed a standardized step test involving three minutes of seated rest, five minutes of stepping at 22.5 steps per minute on a platform 35 centimeters high for women and 40 centimeters for men, and four minutes of seated recovery. Throughout the protocol, a finger-clip pulse oximeter continuously recorded heart rate and peripheral oxygen saturation, while investigators monitored pulse waveforms to discard any artifactual readings.

Days later, the same participants boarded a commercial flight from Beijing to Lhasa, followed by a bus transfer to an experimental base, with all arrivals synchronized between 14:00 and 15:00 to minimize travel-fatigue confounds. The following morning, 18 hours after arrival, researchers administered the Lake Louise Score, the widely used self-report instrument for AMS, under blinded conditions in an independent space. Nineteen of the 44 participants met the diagnostic criteria for AMS, defined as a score of 3 or greater with headache plus at least one additional symptom.

Back at low altitude, the physiological data told a clear story. Variables captured during exercise and recovery, including estimated maximal oxygen uptake, exercise oxygen saturation, recovery oxygen saturation, exercise heart rate, recovery heart rate, and a composite step index, were all significantly correlated with subsequent AMS severity. In contrast, resting heart rate and resting oxygen saturation showed no meaningful association. This distinction matters physiologically: a resting baseline rarely exposes hidden limitations in ventilatory or cardiovascular compensation, whereas the added oxygen demand of exercise can reveal subtle deficits in how efficiently the body shuttles and utilizes oxygen, mimicking in miniature the stress that sudden altitude exposure imposes.

To translate these observations into a classification framework, the researchers applied k-means clustering, an unsupervised machine learning algorithm that groups individuals based on similarity of features without requiring predefined labels. After standardizing the data and reducing dimensionality with principal component analysis, the team tested multiple combinations of physiological variables. The strongest and most accurate stratification emerged from four indicators: estimated VO2max, exercise oxygen saturation, recovery oxygen saturation, and the step index. This combination yielded a silhouette coefficient of 0.767, indicating a strong two-cluster structure, and achieved a within-cohort accuracy of 93.18 percent when evaluated against the actual Lake Louise classifications.

Perhaps most striking was the sensitivity of the approach. All 19 participants who developed AMS were assigned to the AMS-susceptible cluster, and none of the 22 participants in the non-susceptible cluster developed symptoms. The authors are careful to note that these figures represent within-cohort clustering performance rather than validated predictive accuracy in an independent sample, and that no false-negative assignments in a new cohort cannot be guaranteed. Nevertheless, the effect sizes separating the two clusters were substantial, with Cohen’s d values ranging from 0.99 for estimated VO2max to 1.75 for the step index, and the Lake Louise Score itself differed markedly between clusters.

The team went to considerable lengths to confirm the clustering was not an artifact. Bootstrap resampling across 3000 replicates produced a median Jaccard stability index of 0.803, well within the range considered stable. Alternative algorithms including fuzzy c-means, partitioning around medoids, Gaussian mixture models, spectral clustering, and Ward hierarchical clustering broadly reproduced the same partition. When estimated VO2max was deliberately perturbed with realistic measurement error, or excluded entirely, the core structure persisted with only modest degradation. Sex, which some prior studies have linked to AMS susceptibility, showed no significant association with cluster membership, and statistically removing sex-related differences in estimated fitness left every participant in their original cluster.

The most influential single variable turned out to be the step index, a simple composite derived from recovery heart rates and exercise duration. Though modest alone, it combined powerfully with exercise oxygenation measures to separate the two physiological phenotypes. The authors suggest this reflects the fundamental importance of cardiorespiratory reserve: people whose bodies recover quickly from submaximal exertion and who maintain oxygen saturation under load appear better equipped to handle the abrupt hypoxic burden of rapid ascent. Three participants classified as susceptible but who scored below the AMS threshold may represent individuals with genuinely compromised reserves or, alternatively, conservative symptom self-reporting that underestimated their true Lake Louise Scores.

The implications for public health and occupational medicine are considerable. Mountaineers, military personnel, railway and construction workers, pilgrims, and ordinary tourists all stand to benefit from a screening method that requires nothing more than a step platform, a pulse oximeter, and twelve minutes of time. Unlike hypoxic chamber tests or blood-based omics panels, the protocol is easily standardized and could plausibly be administered at worksites, travel clinics, or recruitment centers. The authors emphasize that the approach remains exploratory and requires validation in larger, more diverse cohorts spanning different ages, health statuses, ascent profiles, and altitude targets, and that severe outcomes such as high-altitude cerebral or pulmonary edema were not represented in this young, healthy sample. Still, the study demonstrates that meaningful physiological structure emerges from a test simple enough to be administered almost anywhere, offering a glimpse of a future in which altitude illness risk can be identified and mitigated before the first symptom ever appears.

Subject of Research: Prediction of acute mountain sickness susceptibility using low-altitude step test data and unsupervised machine learning clustering

Article Title: Clustering analysis of acute mountain sickness susceptibility among young adults during rapid ascent using low‐altitude step test data

Article References: Clustering analysis of acute mountain sickness susceptibility among young adults during rapid ascent using low‐altitude step test data. (n.d.). https://doi.org/10.14814/phy2.71091

Image Credits: AI Generated

DOI: 10.14814/phy2.71091

Keywords: acute mountain sickness, step test, k-means clustering, hypoxia, high altitude, machine learning, oxygen saturation, cardiorespiratory fitness, Lake Louise Score, rapid ascent, pulse oximetry, physiological screening